



# Financial Results First Quarter FY2024

**Nitto Denko Corporation**

July 26, 2024

***Nitto***

Innovation for Customers

**1**

**Results of 1Q FY2024**

P3

**2**

**Full-year Forecasts for FY2024**

P12

**3**

**Supplementary Data**

P16

1

# Results of 1Q FY2024

# Summary of Financial Results

## Results of 1Q FY2024

Revenue	<b>249.3 B. yen</b>
---------	---------------------

Operating profit	<b>50.7 B. yen</b>
------------------	--------------------

## YoY

Revenue	<b>+40.9 B. yen</b> (+19.6%)
---------	---------------------------------

Operating profit	<b>+28.3 B. yen</b> (+126.2%)
------------------	----------------------------------

- For Industrial Tape and Optronics, both revenue and operating profit increased.
- For Human Life, revenue increased, while operating profit decreased.
- Impact of yen weakness on operating profit was 11.3 B. yen.

# 1Q FY2024 Results

(Billion yen)


	1Q FY2023 (Apr.-Jun.)	1Q FY2024 (Apr.-Jun.)	YoY	
			Dif.	%
Revenue	208.5	249.3	+40.9	+19.6%
Operating profit	22.4	50.7	+28.3	+126.2%
Operating profit to revenue	10.8%	20.3%	+9.6%	—
Profit before income taxes	22.2	50.6	+28.4	+128.2%
Net profit attributable to owners of the parent company	15.2	36.1	+21.0	+138.2%
Yen/1US\$	135.1	154.6	+19.5	+14.4%

# 1Q FY2024 YoY Operating Profit Change Analysis

(Billion yen)

\*Figures in analysis are estimates

• 1Q FY2023 : Reactionary decrease in profit due to insurance proceeds received for a fire at a Korean subsidiary, etc. -3.0  
 • 1Q FY2024 : Gain on liquidation of a subsidiary, etc. +1.0




# 1Q FY2024 QoQ Operating Profit Change Analysis

(Billion yen)

\*Figures in analysis are estimates

- 4Q FY2023 : Reactionary increase in impairment loss on Personal Care Materials, etc. +1.0
- 1Q FY2024 : Gain on liquidation of a subsidiary, etc. +1.0




# 1Q FY2024 Results by Segment

(Billion yen)

Upper row: Revenue Lower row: Operating profit	1Q FY2023 (Apr.-Jun.)	1Q FY2023 (Apr.-Jun.)	YoY	
			Dif.	%
Industrial Tape	80.7	89.2	+8.5	+10.5%
	7.5	11.5	+4.0	+53.8%
Optronics	104.4	135.8	+31.4	+30.1%
	20.0	45.4	+25.4	+126.9%
Human Life	29.3	31.5	+2.2	+7.6%
	-2.9	-3.2	-0.2	—
Others	0.0	0.0	-0.0	-69.4%
	-1.3	-1.8	-0.5	—
Adjustment	-5.9	-7.2	-1.3	—
	-0.9	-1.3	-0.4	—
Total	208.5	249.3	+40.9	+19.6%
	22.4	50.7	+28.3	+126.2%



# Results by Segment: Industrial Tape



Revenue	<b>89.2 B. yen</b> (YoY +10.5%)
Operating profit	<b>11.5 B. yen</b> (YoY +53.8%)

## ■ Electronics

- Demand for assembly materials used in high-end smartphones increased due to the expansion of models adopting these materials.
- Demand for process materials used in ceramic capacitors continued its gradual recovery.

## ■ Process Materials

- Demand for process materials used in semiconductor memories continued its gradual recovery.

## ■ Others

- In automotive materials, demand for insulation materials used in hybrid vehicles increased.

## Revenue

(Billion yen)

■ Information Fine Materials    ■ Circuit Materials

104.4

17.7

86.6

1Q FY2023  
(Apr.-Jun.)

135.8

30.7

105.1

1Q FY2024  
(Apr.-Jun.)

## Operating profit/Operating profit to revenue

(Billion yen)

19.2%

20.0

1Q FY2023  
(Apr.-Jun.)

33.5%

45.4

1Q FY2024  
(Apr.-Jun.)

Revenue	<b>135.8 B. yen</b> (YoY +30.1%)
Operating profit	<b>45.4 B. yen</b> (YoY +126.9%)



### ■ Information Fine Materials

- Demand for optical films and other peripheral materials increased, as the productions of high-end smartphones by Chinese manufacturers, Electric Vehicles (EV) and Plug-in Hybrid Electric Vehicles (PHEV) remained strong.
- Demand for transparent conductive films (ITO) for tablets increased.

### ■ Circuit Materials

- In Circuit Integrated Suspension (CIS), demand for Hard Disk Drives (HDDs) with high capacity used in data centers increased significantly.
- Demand for high-precision circuits used in high-end smartphones increased.

# Results by Segment: Human Life



Revenue	<b>31.5 B. yen</b> (YoY +7.6%)
Operating profit	<b>-3.2 B. yen</b> (YoY -)

## ■ Life Science

- Demand for nucleic acid synthesis materials (NittoPhase™) increased.
- Preparation is underway at our new plant established in Massachusetts, United States for production of projects that are expected to be commercialized at a future date.
- In nucleic acid drug discovery, Phase 1 clinical trial of intractable cancer drug has been completed. We are continuing to work toward out-licensing our pipeline.

## ■ Membrane

- Demand for high-polymer separation membrane for various industrial applications decreased, mainly in China.

## ■ Personal Care Materials

- Profitability improved as sales of new products for diapers and environmentally friendly products using biodegradable technologies expanded.

## 2

## Full-year Forecasts for FY2024

# Full-year Forecasts for FY2024

13

(Billion yen)

	FY2023 (Apr.-Mar.)	FY2024 Forecasts (Apr.-Mar.)	YoY	
			Dif.	%
Revenue	915.1	982.0	+66.9	+7.3%
Operating profit	139.1	180.0	+40.9	+29.4%
Operating profit to revenue	15.2%	18.3%	+3.1%	—
Profit before income taxes	138.9	180.0	+41.1	+29.6%
Net profit attributable to owners of the parent company	102.7	130.0	+27.3	+26.6%
Yen/1US\$	143.9	153.6	+9.7	+6.7%

# Full-year Forecasts for FY2024 by Segment

14

(Billion yen)

Upper row: Revenue Lower row: Operating profit	FY2023	FY2024 Forecasts	YoY	
	(Apr.-Mar.)	(Apr.-Mar.)	Dif.	%
Industrial tape	352.2	369.5	+17.3	+4.9%
	39.3	50.5	+11.2	+28.6%
Optronics	469.9	492.5	+22.6	+4.8%
	124.0	145.5	+21.5	+17.4%
Human Life	124.5	139.0	+14.5	+11.6%
	-9.5	-0.5	+9.0	—
Others	0.0	-	-	—
	-5.7	-7.5	-1.8	—
Adjustment	-31.4	-19.0	+12.4	—
	-9.0	-8.0	+1.0	—
Total	915.1	982.0	+66.9	+7.3%
	139.1	180.0	+40.9	+29.4%

<Notes regarding this material>

1. Forward-looking statements such as those relating to earnings forecasts and other projections contained in this material are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties and other factors. Accordingly, actual results may differ materially from those projected due to various factors.
2. Amounts and rates (%) are rounded off to the nearest whole unit.


## 3

## Supplementary Data



# Capital Expenditure, Depreciation and Amortization, R&D Expenditure

(Billion yen)




# Consolidated Cash Flow Statement

18

(Billion yen)

	1Q FY2023 (Apr.-Jun.)	1Q FY2024 (Apr.-Jun.)	YoY
Cash flows from operating activities (Operating CF)	11.6	31.6	+20.0
Cash flows from investing activities (Investment CF)	-14.9	-32.1	-17.2
Free cash flow (FCF)	-3.3	-0.6	+2.8
Cash flows from financing activities (Financial CF)	-47.7	-35.5	+12.2
Effect of exchange rate changes on cash and cash equivalents	9.4	9.6	+0.2
Net increase (decrease) in cash and cash equivalents	-41.6	-26.5	+15.2
Cash and cash equivalents at the end of the period	288.3	315.8	+27.5

# Performance Trend (Quarterly)



# Shareholder Returns

- Acquired 30.0 B. yen of treasury shares from February to May in 2024.
- Scheduled the stock split (five-for-one) effective as of October 1, 2024.

Acquisition of treasury shares (Billion Yen)


20.0

47.8

50.0

50.0

30.0



\*The Company resolved, at a meeting of its Board of Directors on May 2024, to implement the five-for-one common stock split, effective as of October 1, 2024. The interim dividend for the fiscal year ending March 31, 2025, on the record date of September 30, 2024, will be paid based on the number of shares before the stock split. The year-end dividend forecast for the fiscal year ending March 31, 2025, describes both of dividend forecast before the stock split and after the stock split.

# Business Portfolio Status

\*Component ratios not including Adjustment  
(Rates (%) are rounded off)


## Revenue

Industrial Tape


Optronics

Human Life


FY2022 results  
929.0 B. yen  
(134.7¥/\$)



FY2023 results  
915.1 B. yen  
(143.9¥/\$)



FY2024 forecasts  
982.0 B. yen  
(153.6¥/\$)



# Business Portfolio Status

\*Component ratios not including Adjustment and negative segments  
(Rates (%) are rounded off)

22

## Operating profit

Industrial Tape


Optronics

Human Life

FY2022 results

147.2 B. yen


(134.7¥/\$)



FY2023 results

139.1 B. yen


(143.9¥/\$)



FY2024 forecasts

180.0 B. yen

(153.6¥/\$)



# Disclosure Segment Categories

Disclosed on April 26, 2022

Disclosed on July 26, 2022

Updated on April 26, 2023

Segment	
Industrial Tape	
Optronics	Information Fine Materials
	Flexible Printed Circuits
Human Life	Life Science
	Membrane
Others (New businesses)	

Segment	
Industrial Tape	
Optronics	Information Fine Materials
	Flexible Printed Circuits
Human Life	Life Science
	Membrane
	Personal Care Materials
Others (New businesses)	

Segment	
Industrial Tape	
Optronics	Information Fine Materials
	Circuit Materials
Human Life	Life Science
	Membrane
	Personal Care Materials
Others (New businesses)	



***Nitto***

Innovation for Customers